Coccidioidomycosis, also known as Valley fever, is a disease caused by the fungal pathogen
Coccidioides
. Unfortunately, patients are often misdiagnosed with bacterial pneumonia, leading to inappropriate antibiotic treatment. The soil
Bacillus subtilis
-like species exhibits antagonistic properties against
Coccidioides in vitro
; however, the antagonistic capabilities of host microbiota against
Coccidioides
are unexplored. We sought to examine the potential of the tracheal and intestinal microbiomes to inhibit the growth of
Coccidioides in vitro
. We hypothesized that an uninterrupted lawn of microbiota obtained from antibiotic-free mice would inhibit the growth of
Coccidioides,
while partial
in vitro
depletion through antibiotic disk diffusion assays would allow a niche for fungal growth. We observed that the microbiota grown on 2×GYE (GYE) and Columbia colistin and nalidixic acid with 5% sheep’s blood agar inhibited the growth of
Coccidioides
, but microbiota grown on chocolate agar did not. Partial depletion of the microbiota through antibiotic disk diffusion revealed diminished inhibition and comparable growth of
Coccidioides
to controls. To characterize the bacteria grown and identify potential candidates contributing to the inhibition of
Coccidioides
, 16S rRNA sequencing was performed on tracheal and intestinal agar cultures and murine lung extracts. We found that the host bacteria likely responsible for this inhibition primarily included
Lactobacillus
and
Staphylococcus
. The results of this study demonstrate the potential of the host microbiota to inhibit the growth of
Coccidioides in vitro
and suggest that an altered microbiome through antibiotic treatment could negatively impact effective fungal clearance and allow a niche for fungal growth
in vivo
.
IMPORTANCE
Coccidioidomycosis is caused by a fungal pathogen that invades the host lungs, causing respiratory distress. In 2019, 20,003 cases of Valley fever were reported to the CDC. However, this number likely vastly underrepresents the true number of Valley fever cases, as many go undetected due to poor testing strategies and a lack of diagnostic models. Valley fever is also often misdiagnosed as bacterial pneumonia, resulting in 60%–80% of patients being treated with antibiotics prior to an accurate diagnosis. Misdiagnosis contributes to a growing problem of antibiotic resistance and antibiotic-induced microbiome dysbiosis; the implications for disease outcomes are currently unknown. About 5%–10% of symptomatic Valley fever patients develop chronic pulmonary disease. Valley fever causes a significant financial burden and a reduced quality of life. Little is known regarding what factors contribute to the development of chronic infections and treatments for the disease are limited.